# Histotype-tailored therapy

Source: https://onco.cc/terms/sarcoma-histotype-tailoring/  
OnCo record `sarcoma-histotype-tailoring` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Histotype-tailored therapy means choosing treatment by the specific sarcoma subtype (there are more than 70) rather than treating all sarcomas alike.

## Summary

Examples: imatinib for GIST, trabectedin for leiomyosarcoma and liposarcoma, eribulin for liposarcoma, pazopanib for non-adipocytic STS, nirogacestat for desmoid, vimseltinib for TGCT, tazemetostat for epithelioid sarcoma (withdrawn 2026), afami-cel for synovial sarcoma, larotrectinib for NTRK fusions. ISG-STS 1001 showed histotype-tailored neoadjuvant chemotherapy was not superior to standard epirubicin-ifosfamide, so tailoring applies mainly to targeted agents.

## Fields

- Kind: Term
- Last checked: 2026-09-07

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Soft-tissue_sarcoma
- Gronchi et al., ISG-STS 1001: histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in high-risk soft-tissue sarcoma (Lancet Oncology 2017): https://doi.org/10.1016/S1470-2045(17)30334-0

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Soft tissue sarcoma of the extremity (localised and advanced)](https://onco.cc/cancers/extremity-soft-tissue-sarcoma/)
- drugs: [Trabectedin](https://onco.cc/drugs/trabectedin/)
- trials: [ISG-STS 1001](https://onco.cc/trials/isg-sts-1001/)
- bottlenecks: [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/)
- ideas: [A same-week expert second opinion for every rare cancer diagnosis](https://onco.cc/ideas/idea-bio2-rare-cancer-telepathology-network/)

---
JSON: https://onco.cc/api/v1/entities/sarcoma-histotype-tailoring.json